<DOC>
	<DOCNO>NCT01653106</DOCNO>
	<brief_summary>The purpose study compare effect short-term ( 2 hours/120 minute ) long-term ( 6 hours/360 minute ) schedule crush ice therapy ( cryotherapy ) . Patients receive high dose melphalan bone marrow transplantation commonly develop significant mouth pain sore ( oral mucositis ) unless cryotherapy utilize . The goal study scientifically determine ( use randomization large sample size ) short-term schedule effective standard long-term schedule preventing , minimize symptom involve oral mucositis . The study also try determine best dose melphalan patient 's body break melphalan obtain blood central venous catheter measure amount melphalan patient 's blood specific time melphalan infused</brief_summary>
	<brief_title>Randomized Trial Cryotherapy Duration Prior High Dose Melphalan Myeloma Patients</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To measure maximum inpatient mucositis grade 120- vs. 360-minutes standardized cryotherapy regimens patient multiple myeloma undergo autologous hematopoietic stem cell transplantation Ohio State Medical Center . SECONDARY OBJECTIVES : I . To develop pharmacokinetic model predict variability unbound serum melphalan area concentration-time curve ( AUC ) . II . To compare neutropenic fever bacteremia incidence 120- vs. 360-minute cryotherapy regimen . III . To compare patient-reported mucositis-related symptom discharge utilize Patient-Reported Oral Mucositis Symptoms Scale ( PROMS ) 120- vs 360-minute cryotherapy regimen . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Beginning fifteen minute melphalan treatment , patient receive 1 ounce shave ice mouth , allow melt replenish immediately 120 minute . ARM II : Beginning fifteen minute melphalan treatment , patient receive 1 ounce shave ice mouth , allow melt replenish immediately 360 minute .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients must diagnose multiple myeloma admit autologous stem cell transplantation Age &gt; 18 year Patients legal representative must able read , understand provide inform consent participate trial Any medical condition , include mental illness substance abuse , deem principal investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cryotherapy</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Mucositis</keyword>
</DOC>